Eye Surgical Robotics Technology Secures $125 Million in Series B Funding from ForSight Robotics

In a significant move for the field of ophthalmology, ForSight Robotics, a pioneer in ophthalmic robotic surgery, has completed a $125 million Series B round led by Eclipse. The funding round saw significant participation from an undisclosed strategic investor, Dr. Fred Moll, the Adani Group, Reiya Ventures, and other existing investors.

The funding will accelerate the next growth phase for ForSight Robotics' flagship product, the ORYOM Platform. Engineered for precise and consistent ophthalmic procedures, the ORYOM Platform is designed to deliver unprecedented dexterity and maneuverability. It aims to provide surgeons with an improved ergonomic experience and can reach any point within the human eye.

Seth Winterroth, partner at Eclipse, believes that ForSight Robotics is at the forefront of a transformation in surgical robotics. He states, "ForSight Robotics is positioning itself to set a new standard in eye care and drive innovation on a global scale."

Dr. Joseph Nathan, co-founder of ForSight Robotics, sees ophthalmology as the next frontier in the robotics revolution. He compares the opportunity in ophthalmology to the rise of Intuitive Surgical in general surgery, stating, "We believe that the ORYOM Platform has the potential to revolutionize ophthalmic surgery in the same way that the da Vinci surgical system has transformed general surgery."

ForSight Robotics benefits from the expertise of a world-class clinical advisory board. Over two dozen ophthalmic surgeons have completed hundreds of procedures on animal eye models with the ORYOM Platform. Mr. Winterroth implies that ForSight Robotics is tapping into a massive, underserved market. According to Dr. Nathan, the market size in ophthalmology is comparable and there is an urgent global need, implying a vast opportunity ahead for ForSight Robotics.

The strategic investor involved in the financing round of ForSight Robotics who was not officially named has not been disclosed in the available search results. However, it is worth noting that Dr. Fred Moll, the founder of Intuitive Surgical and the da Vinci surgical system, joined ForSight Robotics' board of directors.

This round brings ForSight Robotics' total funding to $195 million. The company has also expanded its executive team, received a ISO 13485:2016 certification, and doubled in size, surpassing 110 employees. With the new funding, ForSight Robotics is preparing for first-in-human clinical trials this year, marking a significant step towards the commercialization of the ORYOM Platform.

Mr. Winterroth suggests that ForSight Robotics has a breakthrough approach to ophthalmic surgery. He believes the potential impact of ForSight Robotics' technology on global eye care is extraordinary. As the company continues to make strides in the field, it is poised to redefine the future of ophthalmic surgery and revolutionize eye care on a global scale.